Get the Stockscreener App
14.01
1.08%
0.15
After Hours:
14.10
0.09
+0.64%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $14.01, with a volume of 9.36M.
It is up +1.08% in the last 24 hours and up +3.70% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$13.86
Open:
$13.8
24h Volume:
9.36M
Relative Volume:
0.94
Market Cap:
$16.31B
Revenue:
$14.29B
Net Income/Loss:
$-3.51B
P/E Ratio:
-4.7326
EPS:
-2.9603
Net Cash Flow:
$1.85B
1W Performance:
+2.94%
1M Performance:
+3.70%
6M Performance:
+38.71%
1Y Performance:
+89.58%
1-Day Range:
$13.67
$14.02
1-Week Range:
$13.37
$14.02
52-Week Range:
$7.39
$16.47
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.01 | 16.14B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
17.78 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
119.04 | 50.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.59 | 43.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.26 | 36.81B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
580.51 | 25.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Popular anxiety medication recalled nationwide after FDA warning - NewsNation
Xanax XR recalled after discovery that tablets may fail to release medication properly - Fox Business
Viatris (VTRS) CCO nets 107,135 shares after RSU and DEU vesting - Stock Titan
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Why the Xanax recall may not impact your prescription - The Hill
Popular Prescription Medication Xanax Is Being Recalled Nationwide - AOL.com
Xanax from West Virginia-based company recalled nationwide. What you need to know - Yahoo
Xanax bottles recalled nationwide over dissolution issues - WCVB
Anxiety drug Xanax recalled nationwide: How to check if your prescription is included - New York Post
Xanax, popular anxiety medication, recalled: What to know - FOX 13 Tampa Bay
Popular anxiety drug Xanax recalled nationwide: What to know - NBC 5 Chicago
Bottles of Xanax, a popular anxiety drug, recalled nationwide. Here’s why - KFOR.com
Popular anxiety prescription recalled nationwide - WJHL
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 - Lelezard
FDA Recalls and Warnings: Potentially Contaminated Cough Drops and Eye Drops, Subpotent Thyroid Medications & More - MedShadow Foundation
What to watch May 7: Viatris posts Q1 results, holds webcast - Stock Titan
Behavioral Patterns of VTRS and Institutional Flows - Stock Traders Daily
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Announces Multiple Data Presentations at ASCRS Annual Meeting - National Today
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Xanax Has Been Recalled Nationwide, According to a New FDA Report - The Healthy @Reader's Digest
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - PR Newswire
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Momentum Shift: Is Viatris Inc impacted by rising ratesWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating - Moomoo
VTRS INVESTOR NOTICE: Viatris, Inc. Investors with Substantial L - GuruFocus
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viagra Maker Blocks Rival's 'Kamagra' TM - Law360
Viatris sets long-term targets ahead of investor event - MSN
Layoff Tracker: BioNTech will close Singapore plant, affecting 85 employees - BioSpace
How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc (VIA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Viatris (VTRS) Valuation In Focus After MR-139 Phase III Failure And Pipeline Setback - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris (VTRS) 2026 proxy details $14.3B revenue, board refresh and key votes - Stock Titan
Viatris Inc (VIA.HM) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Viatris Inc. (VTRS) Stock forecasts - Yahoo Finance UK
(VTRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - businesswireindia.com
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)? - simplywall.st
VTRS PE Ratio & Valuation, Is VTRS Overvalued - Intellectia AI
ACC26 conference visit sees Viatris stock decline amid persistent negative momentum and oversold levels - tradersunion.com
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up - TipRanks
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - GuruFocus
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.55%
2.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):